evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

210 questions · 219 findings · 12 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 37 · 16.9%GRADE not reported 16 · 7.3%Very low 60 · 27.4%Low 44 · 20.1%Moderate 53 · 24.2%High 9 · 4.1%

Pericyazine vs Typical antipsychotics

Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia

It is very uncertain whether pericyazine changes global state ‐ not improved compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs Typical antipsychotics

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs Typical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia

It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review